Obesity Drugs Cost Concerns Not Yet Impacting HHS Risk Adjustment Models

 
• By Cathy Kelly

Individual and small group plans in the commercial insurance market are not seeing ‘a large enough change in clinical indications or practice patterns to warrant a change to the current mapping of GLP-1 drugs,’ final rule states.

weight-scale-with-a-tight-belt
Insurance plans worry they will need to tighten their belts because of GLP-1 spending. • Source: Shutterstock

More from Market Access

More from Pink Sheet